0000950170-24-041450.txt : 20240403 0000950170-24-041450.hdr.sgml : 20240403 20240403200055 ACCESSION NUMBER: 0000950170-24-041450 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240401 FILED AS OF DATE: 20240403 DATE AS OF CHANGE: 20240403 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Lyon Joseph Douglas CENTRAL INDEX KEY: 0001817838 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-50679 FILM NUMBER: 24821077 MAIL ADDRESS: STREET 1: C/O CORCEPT THERAPEUTICS INCORPORATED STREET 2: 149 COMMONWEALTH DRIVE CITY: MENLO PARK STATE: CA ZIP: 94025 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: CORCEPT THERAPEUTICS INC CENTRAL INDEX KEY: 0001088856 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 770487658 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 149 COMMONWEALTH DRIVE CITY: MENLO PARK STATE: CA ZIP: 94025 BUSINESS PHONE: 650.688.8803 MAIL ADDRESS: STREET 1: 149 COMMONWEALTH DRIVE CITY: MENLO PARK STATE: CA ZIP: 94025 4 1 ownership.xml 4 X0508 4 2024-04-01 0001088856 CORCEPT THERAPEUTICS INC CORT 0001817838 Lyon Joseph Douglas C/O CORCEPT THERAPEUTICS INCORPORATED 149 COMMONWEALTH DRIVE MENLO PARK CA 94025 false true false false See Remarks true Common Stock 2024-04-01 4 M false 500 11.35 A 7814 D Common Stock 2024-04-01 4 S false 500 26.0070 D 7314 D Stock option (right to buy) 11.35 2024-04-01 4 M false 500 0.00 D 2029-02-08 Common Stock 500 42667 D Includes 1,411 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 1, 2023, 361 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 1, 2023, 460 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 1, 2023, and 507 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 1, 2024. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements The transaction was made pursuant to a 10b5-1 plan in effect at the time of the transaction. Fully exercisable. Chief Accounting & Technology Officer /s/ Joseph Douglas Lyon 2024-04-03